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Purpose: The high expense of newer, more effective adjuvant endocrine therapy agents (aromatase inhibitors [AIs])
for postmenopausal breast cancer contributes to socioeconomic disparities in breast cancer outcomes. This study
compares endocrine therapy costs for breast cancer patients during the first five years of Medicare Part D
implementation, and when generic alternatives became available.
Methods: The out of pocket patient costs for AIs and tamoxifen under Medicare Part D drug plans were determined
for 2006–2011 from the CMS Website for the 50 US states and District of Columbia.
Results: Between 2006 and 2010, the mean annual patient drug cost under Medicare Part D in the median state rose
19% for tamoxifen, 113% for anastrozole, 89% for exemestane, and 129% for letrozole, resulting in median annual out
of pocket costs in 2010 of $701, $3050, $2804, and $3664 respectively. However, the 2011 availability of generic AI
preparations led to median annual costs in 2011 of $804, $872, $1837, and $2217 respectively. Not included in the
reported patient costs, the mean monthly drug premiums in the median state increased 58% in 2011 compared to 2007.
Conclusions: The more effective AI agents became considerably more expensive during the first several years of the
Medicare Part D program. Cost decreased with the introduction of generic agents, an intervention that was independent
of the Part D program. It is unlikely that the Part D program ameliorated existing socioeconomic disparities in survival
among breast cancer patients, but the availability of generic agents may do so.
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Adjuvant oral endocrine therapy for breast cancer repre-
sents one of the most important advances in treatment
in the past several decades. The efficacy of tamoxifen for
the 75% of postmenopausal breast cancer patients with
hormone receptor positive disease was initially demon-
strated by the mid-1980’s, and dozens of trials have shown
that such women randomized to 5 years of tamoxifen
therapy have a 47% reduction in breast cancer recurrence
and 26% reduction in mortality at 10 years compared
to placebo (Early Breast Cancer Trialists’ Collaborative
Group 1998; Early Breast Cancer Trialists’ Collaborative* Correspondence: anatting@mcw.edu
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in any medium, provided the original work is pGroup 2005). More recently, trials have demonstrated that
aromatase inhibitor (AI) agents further reduce breast can-
cer recurrence rates by 30-50% compared to tamoxifen
alone among postmenopausal women with hormone re-
ceptor positive disease (Dowsett et al. 2010). Since early
2005, the American Society of Clinical Oncology has rec-
ommended that all such women be offered AI therapy ei-
ther alone or in sequential combination with tamoxifen
(Winer et al. 2005); other influential groups have made
similar recommendations (Carlson et al. 2006).
While the AI agents are more effective than tamoxifen
in preventing breast cancer recurrence, these drugs have
historically been substantially more costly. This cost dif-
ferential has led to marked socioeconomic disparities in
their use. For example, the use of AI agents (compared
to tamoxifen) is more likely among breast cancer survivors
who are wealthier, who have pharmaceutical insuranceis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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justment for a variety of demographic factors (Yen et al.
2011). Additionally, breast cancer survivors taking AI
agents are more likely to experience financial difficulty
than those taking tamoxifen despite controlling for house-
hold income and drug insurance coverage (Pezzin et al.
2009).
Until 2006, the Medicare program did not provide cover-
age for oral, self-administered pharmaceutical agents.
Effective in 2006, the Medicare Prescription Drug, Im-
provement and Modernization Act added a prescription
drug benefit for enrollees who opted to participate in
its “Part D” voluntary program providing coverage for
such pharmaceutical agents (Kaiser and Foundation 2010).
However, Medicare coverage of prescription drugs under
Part D relies on private plans which are allowed wide dis-
cretion when setting plan features and prices. The result-
ing multitude of plans raises concern about variation in
drug coverage and cost.
This paper documents variation in the costs to breast
cancer patients of alternative Part D drug plans and of
the relevant oral endocrine agents during the first sev-
eral years of the Part D program, as well as the extent to
which these costs changed during the first full year for
which generic formulations were available. Adjuvant endo-
crine therapy for breast cancer is a useful area for study as
there are only a limited number of pertinent oral pharma-
ceutical agents. In addition, the three newer, more expen-
sive, and more effective AI agents (anastrozole, exemestane,
and letrozole) can be contrasted to tamoxifen, the older,
less expensive and less effective agent.
Methods
Source of data
We assembled information on the Part D plans available
to Medicare beneficiaries in each state and the District
of Columbia by manually querying the Centers for
Medicare and Medicaid Services (CMS) website used by
Medicare beneficiaries to find and compare the Part D
plans available in their areas (Medicare Plan Finder). For
each plan in each state, information was collected on
deductible amounts, monthly drug premiums and the
specific drug costs for each of the four endocrine agents
of interest (anastrozole, exemestane, letrozole, and
tamoxifen). Drug specific costs collected included the
drug cost after the deductible was met, the cost in the
coverage gap (also known as “doughnut hole”, and reached
after about $2500-3100 [exact amount changes annually]
of out of pocket drug costs in a calendar year), and the
cost under catastrophic coverage (which is reached after
expending about $4500 [exact amount changes annually]
of out-of-pocket drug costs in a calendar year). The annual
drug cost under each plan was also obtained from the
website and represents the aggregate cost to a beneficiarywho took only that drug at recommended dosing for the
entire year, including deductible and drug-specific costs,
but not the plan premiums. The project was approved by
the Medical College of Wisconsin/Froedtert Hospital
Institutional Review Board #5.
Data analysis
While the Medicare Part D program initiated coverage
in 2006, the program provided only partial coverage for
many patients that year; 2007 was the first full year of
coverage for most beneficiaries. In this paper, we focus
on contrasting costs faced by breast cancer patients in
2006 or 2007 (first full year of Part D implementation)
to 2010 (fifth year of Part D implementation) and 2011
(first full year of availability of generic AI agents on CMS
Website). Specifically, the state-specific mean monthly
drug premium costs were computed for plans in each
state. We report the median and range of the state-
specific mean premium costs for each study year. Simi-
larly, for the drug-specific costs, the mean costs were
computed for each state, and we report the median and
range of these state means.
Results
Costs of breast cancer endocrine agents
The drug-specific costs of the adjuvant endocrine agents
most commonly used for early stage breast cancer are
presented for 2007, 2010, and 2011 (Tables 1 and 2).
Four drugs are of interest, specifically, the three FDA-
approved AI agents (anastrozole, exemestane, and letro-
zole) and tamoxifen. Only tamoxifen was available in gen-
eric formulation on the CMS website during 2007–10, but
generic agents were available for each of the AI agents
during 2011. All states had one or more plans providing
coverage for each of these medications; typically, all plans
in a state provided coverage for each medication.
For each plan covering a medication, three costs were
consistently provided for each drug. These were the
monthly cost after the deductible, the monthly cost in
the gap (or “doughnut hole”), and the monthly cost once
catastrophic expense levels were reached. In 2007, nine
states offered at least one “no-cost” plan (that is, after
payment of the deductible, drug offered at no cost until
reaching the doughnut hole) for the three AI agents. In
2010 and 2011, no plans in any state offered a no-cost
plan for AI coverage. In contrast, for tamoxifen, at least
one plan in each state offered a no-cost plan in each study
year.
In 2007, the median monthly cost after deductible was
about $40 for each of the three AI agents (Tables 1 and
2). By 2010, this cost had increased by 58% for anastrozole
and by over 100% for exemestane and letrozole (Table 1).
However in 2011, the first full year of generic availabil-
ity of the AI’s, the monthly cost after deductible for
Table 1 Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents prior to generic
availability
Medication Monthly cost in gap Monthly cost in catastrophic
Median of state mean costs Median of state mean costs Median of state mean costs
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monthly cost for exemestane and letrozole in 2011
moderated compared to 2010, but did remain higher
than the 2007 costs (Table 2). The monthly cost for
tamoxifen fell by less than $1 in both 2010 and 2011.
The cost in the gap of the three aromatase inhibitors
increased from 32% to 56% between 2007 and 2010, but
these costs fell between 9 and 85% between 2007 and
2011. In contrast the cost in the gap of tamoxifen,
already less than one-tenth of the aromatase inhibitor
cost in 2007, fell by 27% in 2010 and by 38% in 2011.
Costs for all medications were much more moderate in
the catastrophic phase. These costs in 2011 compared to
2007 declined for anastrazole, remained about the same
for exemestane, and rose for letrozole and tamoxifen.
Annual drug costs
The annual drug costs represent the aggregate cost to
the patient of taking only a given drug at recommended
dosing for an entire year, including deductible and drug-Table 2 Trajectory of costs under Medicare Part D for breast
availability of generic alternatives
Medication Monthly cost in gap Monthly c
Median of state mean costs Median o




























aFirst year generic formulation was available to Medicare Part D beneficiaries; genespecific costs, but not the plan premiums. Annual drug
costs were not available for 2007; Table 3, therefore, re-
ports the annual drug costs for the three AI agents and
for tamoxifen in 2006, 2010, and 2011. During the first
five years of the Part D drug plan, the median annual
drug cost to the patient for tamoxifen (generic) increased
19% to $701.18 while the median annual drug cost for
anastrozole, exemestane, and letrozole (brand; no generics
provided) rose 113%, 89%, and 129% (to $3050, $2804,
and $3664) respectively. In 2011, the first year of generic
AI availability on the CMS Website, the annual cost to the
patient of anastrozole fell 39% from the 2006 level and
71% from the 2010 level. The costs for exemestane and
letrozole declined more modestly from the 2010 levels, to
costs 24% and 39% above the 2006 levels respectively. In
2006, the ratio of annual cost to the patient for AI com-
pared to tamoxifen was 2.4, 2.5, and 2.7 for anastrozole,
exemestane, and letrozole respectively. In 2010, these ra-
tios were 4.4, 4.0, and 5.2, but in 2011 these ratios fell to
1.1, 2.3, and 2.8 respectively.cancer adjuvant endocrine agents before and after
ost in catastrophic
f state mean costs Median of state mean costs






































Table 3 Annual drug costs for breast cancer adjuvant endocrine agents under medicare Part D and after availability of
generic alternatives
2006 annual costsa 2010 annual costsa 2006 to 2010 2011 annual costsa,b 2006 to 2011 2010 to 2011
Drug Median of state mean
costs










$, (Range of mean
costs)
$, (Range of mean
costs)





























Tamoxifen 588.18 (520.13-648.77) 701.18 (558.66-780.02) +19 804.03 (660.68-881.69) +37 +15
aRange and median of mean annual drug costs of Part D plans across 50 states and the District of Columbia. Annual drug cost values represent the aggregate
cost to the patient of taking only that drug at recommended dosing for an entire year, including deductible and drug-specific costs, but not the plan premiums.
These values were provided directly from the CMS website, and obtained by entering the relevant drug as the only drug to be taken for the year.
bFirst full year in which generic aromatase inhibitor agents were made available to Medicare Part D beneficiaries; generic cost provided.
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In 2007, the number of plans offered on the CMS Web-
site per state ranged from 43 to 64 (median = 51) plans
(Table 4). The number of plans fell to a median of 41 by
2010 and to 33 by 2011, a 35% decline from 2007
(Table 4). The monthly Part D plan premium cost is not
included in the annual out of pocket drug costs shown
in Table 3. The monthly premium costs increased from
about $36 in 2007 to $47 in 2010 and $57 in 2011.
Therefore, in addition to the annual drug costs, patients
were paying a median of about $684 annually by 2011,
up from $432 in 2007.
Discussion
This study documents substantial increases of 89% to
129% in the annual cost to Medicare beneficiaries with
breast cancer of the more effective aromatase inhibitor
agents over the first five years of the Medicare Part D
drug program. However after the 2011 introduction of
generic AI agents, a private sector event unrelated to
Part D, beneficiaries’ costs were much more moderate.
For example, the median out of pocket cost to benefi-
ciaries of anastrozole was $1433 annually in 2006, rose
to $2804 in 2010, and then declined to $872 in 2011.
The relative cost of the three AI agents compared to the
less effective tamoxifen was 4.0 to 5.2 times greater in
2010, but fell to 1.1 to 2.8 times greater in 2011. The in-
crease in AI costs to beneficiaries from 2006 to 2010
was attributable to increases in the monthly cost afterTable 4 Medicare Part D plan characteristics over time
2007
Number of Plans in Each State (Median; Range) 51 (43–64)
Mean Monthly Drug Premium in Each State (Median $, Range) 36.09 (31.72
aFirst full year when generic alternatives to brand name aromatase inhibitors werethe deductible, as well as the monthly cost in the gap
and in the catastrophic phases. The very substantial cost
decreases that accompanied the 2011 introduction of
generic AI’s were largely attributable to the monthly cost
after deductible, with lesser declines in the cost in the
gap for exemestane and letrozole. Not included in the
annual out of pocket drug costs, median plan premiums
rose 58% in 2011 compared to 2007.
Plan benefit design represents a critical public policy
tool for improving access and adherence to needed treat-
ments. Evidence suggests that increased prescription
drug cost sharing, whether in the form of co-payments,
tiering, benefit caps or deductibles, is associated with
lower rates of drug treatment, worse adherence among
existing users and more frequent discontinuation of ther-
apy (Goldman et al. 2004; Soumerai et al. 2006; Goldman
et al. 2007; Zhang et al. 2009; Li et al. 2012). It has been
estimated, for example, that for each 10% increase in cost
sharing, prescription drug spending decreases by 2-6%
depending on class of drug and patient’s circumstances
(Goldman et al. 2007). Assuming these estimates hold
for breast cancer patients, the plan and drug cost in-
creases observed over the initial 5-year period of Part D
implementation may have led to a substantial decline in
use and adherence to the more effective hormonal treat-
ments. Although the guidelines for adjuvant hormonal
therapy in post-menopausal women with breast cancer
permit use of tamoxifen as an endocrine agent, the recom-
mendation is that an AI be offered for all or at least half of2010 2011a % Change in median,
2007 to 2011
41 (34–49) 33 (28–38) −35.3
-40.69) 46.72 (35.12-53.01) 57.08 (44.93-62.97) +58.2
made available to Medicare Part D beneficiaries.
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apy (Winer et al. 2005; Burstein et al. 2010). With recent
recommendation for 10 years of endocrine therapy for
many women, the cost implications become even more
important (Burstein et al. 2014). In the case of breast can-
cer, early discontinuation of adjuvant endocrine therapy is
associated with a greater risk of recurrence and/or death
(Hershman et al. 2010).
Our findings are consistent with reports suggesting
that many of the largest prescription drug plans substan-
tially raised prices since the drug benefit was added to
Medicare (Kaiser and Foundation 2010; Hadley et al.
2009). These results further suggest that, at least with re-
spect to breast cancer, drug cost increases were not uni-
versal across the range of possible oral endocrine agents
but affected the more effective AI drugs to a greater de-
gree. Attempts to streamline the Part D program in re-
sponse to public criticism about the difficulty in finding
the “best” Medicare prescription drug plan, including
eliminating duplicative plans, did result in lower overall
number of plans offered in each market as evidenced by
our 2010–11 results, but may have contributed to in-
creased costs to beneficiaries.
An important goal of the Medicare Part D program
was to reduce medication and socioeconomic-related
disparities in health outcomes (Kaiser and Foundation
2010). An important provision of the later enacted Pa-
tient Protection and Affordable Care Act was to estab-
lish additional help to low income beneficiaries in the
form of the Low Income Subsidy (LIS), a benefit that
provides full or partial subsidies of premiums and reduc-
tions in cost-sharing for Part D. The challenges posed by
the Medicare Part D program enrollment and plan
choice, however, appear to be even greater among this
group (Davidoff et al. 2010). Although Medicare benefi-
ciaries with full Medicaid benefits are automatically
enrolled in Part D, an estimated 2.3 million beneficiar-
ies eligible for the LIS have not applied for the subsidy
(Enrollment Information 2009). Evidence further sug-
gests that those receiving the LIS benefit experience
greater difficulty navigating program information and
making decisions about plans: compared to other Part
D beneficiaries, LIS recipients are less likely to understand
plan features, including premiums and deductibles, or
their rights under Part D, including the right to enroll in a
different plan (Neuman et al. 2007; Hsu et al. 2008).
Previous studies have shown that socioeconomic status,
particularly household income, is related to use of AI
agents. Wealthier women and those with more extensive
insurance coverage are more likely to receive AI therapy
(Yen et al. 2011). Residence in a high poverty area is a risk
factor for failure to receive guideline concordant hormonal
therapy (Wu et al. 2012). High out-of-pocket cost has
been found to be strongly associated with non-adherencewith hormonal therapy agents for breast cancer (Riley
et al. 2011; Hershman et al. 2014). These findings suggest
that the cost of AI agents contributes to the ongoing so-
cioeconomic disparities in survival among breast cancer
patients (Bigby and Holmes 2005). Against the backdrop
of low uptake of the LIS benefit and lack of understanding
about the Part D program among low-income beneficiar-
ies, our results raise questions about whether the Part D
program has led to any amelioration of existing socioeco-
nomic disparities in breast cancer outcomes. It is likely
that the introduction of generic agents was more effective
in mitigating such disparities in breast cancer outcomes.
Our data were gathered from the publicly available
CMS web site used by beneficiaries to compare different
plans available to them. As such, the data represent the
range of choices available to beneficiaries, but not the
actual choices made by those beneficiaries. The distribu-
tion of costs in the plans actually selected by beneficiaries
would be expected to differ somewhat from the distribu-
tion of costs presented herein, as plans are not equally
selected by beneficiaries. In fact, the Kaiser Foundation
conducted an analysis of plans that CMS expected to
be available for 2010, with weighting based on expected
enrollment (Hadley et al. 2009). The projected weighted
monthly drug plan premium based on this analysis was
$38.94, which is lower than the median of the state pre-
miums, which we report to be $46.72 (Table 4). This
implies that Part D participants are choosing plans with
lower premiums than the mean of the available plans.
Supporting this contention, Abaluck and Gruber dem-
onstrated that elderly persons systematically make inef-
ficient drug plan choices and tend to place more weight
on plan premiums than on expected out of pocket costs
(Abaluck and Gruber 2011). Therefore the median an-
nual drug costs reported in this paper may underestimate
the actual median annual drug costs for the population of
Medicare beneficiaries using Part D programs to purchase
endocrine agents for breast cancer.
A limitation of our study is that the CMS web site
may have some inaccuracies. Updates are made to the
web site throughout the calendar year, and these updates
would not necessarily have been captured by us, as we
queried the website early in each calendar year. However,
because most Part D participants select their plans in No-
vember or December for the following calendar year, any
updates made during the calendar year are unlikely to
affect the plan choices made by most participants for that
year. Therefore, it is likely that the information we gath-
ered was the same information used by the majority of
Medicare beneficiaries to make a plan choice for that cal-
endar year.
Early evaluations of the Medicare Part D program have
been generally positive. For example, there is evidence
that cost-related non-adherence fell somewhat in 2006
Nattinger et al. SpringerPlus  (2015) 4:54 Page 6 of 7compared to 2004–5, (Madden et al. 2008) although this
decrease was observed only among beneficiaries in good
to excellent health, and not beneficiaries in fair to poor
health. The implementation of Part D coverage was as-
sociated with a reduction in nondrug medical spending
in 2006–07, compared to 2004–05, for beneficiaries with
limited prior drug coverage (McWilliams et al. 2011).
Satisfaction with the Part D program was high in 2007
(Keenan 2007). However, we show that the situation in
2010 was quite a bit different than in 2006, at least for
breast cancer patients. The substantive changes in bene-
ficiary costs provide justification for continued evalu-
ation of the effectiveness of the program with regard to
multiple constructs.
In conclusion, the costs under the Medicare Part D
program of aromatase inhibitors, the most effective breast
cancer adjuvant endocrine agents, rose dramatically be-
tween 2006 and 2010, and then fell with the availability of
generic AI agents in 2011. These results raise concern
about the degree to which the Medicare Part D plan will
achieve its goals of improving accessibility to life-saving
pharmaceutical agents, and decreasing socioeconomic dis-
parities in outcomes. Rather, the availability of generic
preparations may be more likely to achieve these aims.
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